EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ten Questions for Ethics Committees Evaluating the Strength of Evidence in Support of Early Phase Trials

Spencer Phillips Hey, Mark Fedyk, Jonathan Kimmelman

Ethics & Human Research · 2026-05 · 48 (3) · 6-16

DOI: 10.1002/eahr.70010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ethics & Human Research, online erschienen am 04.05.2026. Verfasst von Spencer Phillips Hey und 2 weiteren Autor:innen. Beteiligte Einrichtung: Founder of Hey Research & Innovation. Hauptthemen laut MEDLINE: Ethics Committees, Research, Clinical Trials as Topic, Translational Research, Biomedical. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Assessing the risks and benefits of early‐phase clinical trials presents a persistent challenge for research ethics committees. These trials often lack direct, supporting evidence of clinical safety and efficacy, requiring ethics reviewers to evaluate a complex, heterogeneous body of preclinical and mechanistic evidence. The Preclinical Assessment for Translation to Humans (PATH) framework provides a systematic method for analyzing the strength of supporting evidence for early‐phase trials. PATH structures the evaluation of risks and benefits into a series of mechanistic steps, guiding ethics committees through a transparent and reasoned assessment of the evidence linking molecular effects to clinical outcomes. However, applying PATH can be time‐intensive and complex. In this article, we propose a streamlined approach—ten key questions that ethics committees can use to apply PATH toward a systematic evaluation of the translational chain of evidence in early‐phase trials. By incorporating this approach, ethics committees can fulfill their duty to protect research participants to ensure that early‐phase trials are ethically and scientifically grounded.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ethics Committees, ResearchClinical Trials as TopicTranslational Research, BiomedicalHumansRisk Assessment

Stichwörter der Autor:innen

clinical translationearly‐phase clinical trialshuman research ethicsinstitutional review boards (IRBs)risk‐benefit evaluationscientific evidence assessment

Autor:innen und Institutionen

  • Founder of Hey Research & Innovation.
  • Professor of bioethics at the University of California, Davis.
  • James McGill Professor of Biomedical Ethics at McGill University.

Förderung

  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Hey, S. P., Fedyk, M., & Kimmelman, J. (2026). Ten Questions for Ethics Committees Evaluating the Strength of Evidence in Support of Early Phase Trials. Ethics & Human Research, 48(3), 6-16. https://doi.org/10.1002/eahr.70010

Vancouver

Hey SP, Fedyk M, Kimmelman J. Ten Questions for Ethics Committees Evaluating the Strength of Evidence in Support of Early Phase Trials. Ethics & Human Research. 2026;48(3):6-16. doi:10.1002/eahr.70010

BibTeX
@article{Hey2026,
  author = {Hey, Spencer Phillips and Fedyk, Mark and Kimmelman, Jonathan},
  title = {Ten Questions for Ethics Committees Evaluating the Strength of Evidence in Support of Early Phase Trials},
  journal = {Ethics & Human Research},
  year = {2026},
  volume = {48},
  number = {3},
  pages = {6--16},
  doi = {10.1002/eahr.70010}
}
Kostenlos starten →